NCT00042510View on ClinicalTrials.gov

Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

August 31, 2000

Primary Completion Date

February 28, 2003

Study Completion Date

July 31, 2004

Conditions
Stomach NeoplasmsEsophageal Neoplasms
Interventions
BIOLOGICAL

Treatment group

Sponsors
All Listed Sponsors
lead

Cancer Advances Inc.

INDUSTRY

NCT00042510 - Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer | Biotech Hunter | Biotech Hunter